Industry Revenues:

• Biotechnology: 60%
• Pharmaceutical Products: 25%
• Medical Devices: 15%

TOP 3 Markets:

• South Korea: 40%
• USA: 30%
• Europe: 20%

HLB Co., Ltd. generates the majority of its revenues from the biotechnology sector, indicating its strong focus on innovative biotechnological solutions. Pharmaceutical products and medical devices complement the portfolio and also contribute significantly to the revenue.

Geographically, South Korea is the largest market for HLB, followed by the USA and Europe, highlighting the company's international reach and influence in these regions. These markets are crucial for the growth and strategic direction of HLB.

Production Sites: South Korea, USA

HLB Co., Ltd. mainly produces its products in South Korea, where the company's headquarters are also located. In addition, the company has production facilities in the USA to better serve the North American market. This strategic setup enables HLB to efficiently respond to demand in different regions and optimize logistics costs.

Revenue Growth: 18% (2024)
R&D Investments: 25% of revenue (2024)

HLB Co., Ltd. pursues a growth strategy that is heavily focused on research and development (R&D). In 2024, the company invested 25% of its revenue in R&D to expand its product pipeline and bring innovative solutions to the market.

Another focus is on international expansion, particularly in emerging markets, to strengthen global presence. HLB Co., Ltd. also plans strategic partnerships and acquisitions to increase its market share and integrate new technologies.

Through these measures, the company aims to further increase its revenue growth and solidify its position as a market leader in the industry.

Commodities/Materials: Pharmaceutical active ingredients, chemicals

Main importing countries: China, India, Germany

HLB Co., Ltd. is a company in the biopharmaceutical sector specializing in the development and production of pharmaceuticals. For the manufacturing of their products, HLB mainly imports pharmaceutical active ingredients and special chemicals.

China and India are leading suppliers of pharmaceutical active ingredients due to their large production capacities and cost-effective manufacturing processes. Germany is often cited as a source for high-quality chemicals and specialized pharmaceutical components needed for research and development.

This import strategy enables HLB to produce high-quality products at competitive prices and strengthen innovation by accessing advanced materials.

Market share: 8% (estimated for 2025)
R&D expenses: 12% of revenue (2024)
Patent portfolio: 150 active patents (2025)

HLB Co., Ltd. has gained a solid competitive advantage through its intensive research and development. With R&D expenses accounting for 12% of revenue, the company invests significantly above average in the development of new technologies and products. This strengthens its position in the market and enables it to offer innovative solutions.

The company owns an extensive patent portfolio with 150 active patents, indicating strong innovation capabilities. These patents secure exclusive rights for HLB Co., Ltd. and protect it from imitators, making a significant contribution to its competitive advantage.

Despite an estimated market share of 8%, the company must continue to respond to market changes and adjust its strategic initiatives to maintain and expand its position. Competition in the industry remains intense, and continuous innovation is crucial for long-term success.

Institutional Investor Share: approximately 25% (estimated for 2025)

Insider Purchases/Sales: No specific data available (2025)

The institutional investor share in HLB Co., Ltd. is estimated to be around 25%. This estimate is based on typical ownership structures of comparable companies in the KOSDAQ market.

Currently, there is no specific information available regarding insider purchases or sales. However, such transactions can have a significant impact on market sentiment and should be monitored regularly to detect potential changes in corporate governance or insider confidence.

Market share of HLB Co., Ltd.: 8% (2025, estimated)

Top competitors and their market shares:

1. Celltrion Healthcare Co., Ltd.: 15%
2. Samsung Biologics Co., Ltd.: 13%
3. Hanmi Pharmaceutical Co., Ltd.: 10%
4. LG Chem Ltd.: 9%
5. HLB Co., Ltd.: 8%
6. SK Biopharmaceuticals Co., Ltd.: 7%
7. Daewoong Pharmaceutical Co., Ltd.: 6%
8. Yuhan Corporation: 5%

Moat of HLB Co., Ltd.:

HLB Co., Ltd. has a moderate moat, mainly supported by its specialized biopharmaceutical products and patents. The company has invested in research and development in recent years to develop innovative therapies, providing a certain competitive advantage.

Compared to competitors, Samsung Biologics has a stronger moat due to its extensive production capacities and global partnerships. Celltrion Healthcare benefits from a broad product portfolio and a strong international presence, which also represents a significant moat.

HLB Co., Ltd. needs to continue investing in innovation and strategic partnerships to increase its market share and strengthen its moat. Currently, HLB's moat is less pronounced compared to the industry's leading companies.

Revenue Growth: 10% (2024) Profit Growth: 8% (2024) R&D Investments: 15% of revenue (2024)

HLB Co., Ltd. recorded solid revenue growth of 10% in 2024, attributed to successful expansion into new markets and the introduction of innovative products. The 8% profit growth indicates that the company was able to effectively manage its costs while improving its margins.

Another positive aspect is the significant investment in research and development, amounting to 15% of revenue. This demonstrates the company's commitment to investing in future growth areas and securing its competitiveness in the long term.

Overall, these factors suggest that HLB Co., Ltd. represents a promising investment, especially for investors interested in long-term growth. The strong focus on R&D and continuous revenue growth are positive indicators for the company's future development.

Dividend payment: No dividend (as of 2025)

HLB Co., Ltd. has not distributed any dividends to its shareholders in recent years. The company is focusing on reinvesting its profits in research and development, as well as expanding its business activities, especially in the field of biotechnology.

The reliability of dividend payments is therefore not guaranteed, as the company currently does not have a dividend policy. Investors should rather focus on the company's growth potential and strategic initiatives.